After Citigroup and Wells Fargo gave Danaher (NYSE: DHR) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Stephen Unger maintained a Buy rating on Danaher today and set a price target of $183.00. The company’s shares closed last Thursday at $161.66.
According to TipRanks.com, Unger is a 5-star analyst with an average return of 13.6% and a 70.5% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $174.88, a 10.6% upside from current levels. In a report issued on May 8, Citigroup also maintained a Buy rating on the stock with a $190.00 price target.
See today’s analyst top recommended stocks >>
Based on Danaher’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.34 billion and net profit of $595 million. In comparison, last year the company earned revenue of $4.22 billion and had a net profit of $334 million.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Earlier this month, Robert S. Lutz, the SVP-Chief Accounting Officer of DHR sold 33,892 shares for a total of $5,479,595.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician’s offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.
Read More on DHR:
